David Sinclair· PhD
With ER-100 on track for human trials in Q1 2026, this program is moving quickly toward patients
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
With ER-100 on track for human trials in Q1 2026, this program is moving quickly toward patients
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
So far, the data suggest ER-100 should be safe in humans, and the FDA has cleared us to move into clinical trials.